News
At Paradigm, we firmly believe that the key to addressing unmet medical needs lies in unlocking the potential of forgotten compounds. Our strategy is to take unconventional routes to develop safe and effective treatments for clinical conditions that lack viable options.
Our current primary focus is the development of injectable pentosan polysulfate sodium (iPPS/Zilosul®), for the treatment of osteoarthritis (OA). An ability to provide a safe an effective treatment for OA is a blockbuster market opportunity as there are limited therapeutic solutions available. We’ve charged ahead into global phase 3 trials, addressing the core components of the disease: inflammation, pain, and regeneration. Zilosul® possesses the remarkable potential to provide long-term pain reduction and modify the underlying course of this debilitating disease.
With our headquarters in Melbourne, Australia, and strategic offices in the European Union and the United States, Paradigm is poised to make a global impact. Our international presence reflects our commitment to delivering ground breaking treatments to patients worldwide.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
ASX Quarterly Wrap: HTG sales momentum continues, Race Oncology appoints CEO
News
ASX Small Caps Lunch Wrap: Who’s come up with a brutal way to get back at your ex on Valentine’s Day?
Health & Biotech
ASX biotechs with big catalysts in 2024: Part 2
Health & Biotech
Paradigm Biopharmaceuticals is transforming the way we treat osteoarthritis
Experts
CRITERION: Paradigm’s set for a proper knees-up if its arthritis fighter is the real deal
Health & Biotech
ASX Health Stocks: IDT on strong growth trajectory, Paradigm smashed 30pc on cap raise
News
10 at 11ish: Magnum Mining inks Saudi deal, Novonix scores US$100m grant
News
Closing Bell: Orbiting the ASX at +220pc, TG Metals successfully separates ahead of ASX hard landing
News
In Case You Missed It: Lithium hits and a West African gold producer in the takeover crosshairs
News
Quarterly wrap: Paradigm and Dimerix advance clinical trials, MME loan book increasingly robust
News
In Case You Missed It: Lithium takeover, a new lithium discovery and a gold asset sale
Health & Biotech
Paradigm jumps 20pc on positive Phase 2 trial osteoarthritis results, including ‘notable increase’ in cartilage thickness
News
In Case You Missed It: Bumper quarter for aged care tech and a global agricultural deal
Health & Biotech
‘Remarkable outcome’: Paradigm achieves outstanding results in phase II osteoarthritis trial
Health & Biotech
ASX Health Stocks: Paradigm to seek TGA nod after successful trial; EMVision uses AI simulation
News
Top 10 at 11: Juicy berries and autonomous cop drones got the market jingling this morning
Health & Biotech